{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:27:18Z","timestamp":1787840838460,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is an autoimmune, T-cell-mediated disorder manifesting as non-scarring alopecia. Treatment consists of corticosteroids, calcineurin inhibitors, prostaglandin analogs, minoxidil, anthralin, vitamin D analogs, and JAK STAT inhibitors. Despite several treatment options, personal opinions regarding the safety and efficacy of a particular treatment are highly variable. This has led the management of AA to be quite challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety between the three molecules, namely mometasone 0.1% ointment, calcipotriol 0.005% ointment, and tacrolimus 0.1% ointment, in localized AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients were randomized into three groups, and topical medications were dispensed for each group in unlabeled tubes. Lesional photographs, dermoscopic images, Severity of Alopecia Tool (SALT) scoring, hair pull test, and Dermatology Life Quality Index questionnaires were done at the baseline visit and at every follow-up visit at 4 weeks and 8 weeks from the baseline visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At the end of 8 weeks, both mometasone and calcipotriol groups had a significant decrease in their SALT scores (&lt;0.001), but the tacrolimus group did not show any significant change in parameters at the end of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>The main drawback is that there was no control group and the vehicle dispensed was ointment formulation, which may have penetration issues. The lack of long-term follow-up is also a limitation of this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both mometasone and calcipotriol formulations were found to be effective in the treatment of localized stable AA; however, calcipotriol preparation was associated with minimal side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_913_23","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T02:01:03Z","timestamp":1740621663000},"page":"248-257","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study"],"prefix":"10.4103","volume":"16","author":[{"given":"Farheen","family":"Begum","sequence":"first","affiliation":[{"name":"Department of DVL, Kalinga Institute of Medical Sciences, Bhubaneshwar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of DVL, IMS and SUM Hospital, Bhubaneshwar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaya K.","family":"Jena","sequence":"additional","affiliation":[{"name":"Department of DVL, IMS and SUM Hospital, Bhubaneshwar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitreyee","family":"Panda","sequence":"additional","affiliation":[{"name":"Department of DVL, IMS and SUM Hospital, Bhubaneshwar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"R1-20250227","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-4362.1996.tb01610.x","article-title":"Profile of alopecia areata in Northern India","volume":"35","author":"Sharma","year":"1996","journal-title":"Int J Dermatol"},{"key":"R2-20250227","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jaad.2006.02.045","article-title":"Alopecia in the United States:Outpatient utilization and common prescribing patterns","volume":"57","author":"McMichael","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2008.03.031","article-title":"The role of scalp dermoscopy in the diagnosis of alopecia areata incognita","volume":"59","author":"Tosti","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250227","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata:An Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"key":"R5-20250227","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study:Results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250227","doi-asserted-by":"crossref","first-page":"950450","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata:A systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"key":"R7-20250227","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0974-7753.66921","article-title":"Bexarotene gel:A new topical therapy for alopecia areata","volume":"2","author":"Rajiv","year":"2010","journal-title":"Int J Trichology"},{"key":"R10-20250227","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0974-7753.82123","article-title":"Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata","volume":"3","author":"Kuldeep","year":"2011","journal-title":"Int J Trichol"},{"key":"R11-20250227","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2340\/0001555572373375","article-title":"The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate","volume":"72","author":"Van","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"R12-20250227","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000371416","article-title":"Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata:A pilot study","volume":"230","author":"Zaher","year":"2015","journal-title":"Dermatology"},{"key":"R13-20250227","doi-asserted-by":"crossref","first-page":"e12574","DOI":"10.1111\/dth.12574","article-title":"Use of adapalene in alopecia areata:Efficacy and safety of mometasone furoate 0.1% cream versus combination of mometasone furoate 0.1% cream and adapalene 0.1% gel in alopecia areata","volume":"31","author":"Unal","year":"2018","journal-title":"Dermatol Ther"},{"key":"R14-20250227","first-page":"616","article-title":"Topical calcipotriol therapy for mild-to-moderate alopecia areata:A retrospective study","volume":"14","author":"\u00c7erman","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"R15-20250227","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s13555-020-00379-7","article-title":"Efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of alopecia areata:An intrasubject pilot study","volume":"10","author":"Molinelli","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R16-20250227","doi-asserted-by":"crossref","first-page":"e12464","DOI":"10.1111\/dth.12464","article-title":"Efficacy and safety of topical calcipotriol in management of alopecia areata:A pilot study","volume":"30","author":"Narang","year":"2017","journal-title":"Dermatol Ther"},{"key":"R17-20250227","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2004.05.019","article-title":"Topical tacrolimus in alopecia areata","volume":"52","author":"Price","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R18-20250227","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/ijt.ijt_18_19","article-title":"Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata","volume":"11","author":"Alam","year":"2019","journal-title":"Int J Trichology"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_913_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:30:03Z","timestamp":1787837403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_913_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_913_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"2023-12-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}